NKGen Biotech Announces Upcoming Presentation On SNK01 NK Cell Therapy In Neurodegenerative Disease At The 12th Annual Alzheimer's & Parkinson's Drug Development Summit
NKGen Biotech Announces Upcoming Presentation On SNK01 NK Cell Therapy In Neurodegenerative Disease At The 12th Annual Alzheimer's & Parkinson's Drug Development Summit
NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson's disease, and highlight clinical safety and efficacy data from the Company's recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer's disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit to be held in Boston, MA, from April 23–25, 2024.
專注於創新型自體、異體和CAR-NK自然殺傷（“NK”）（“NKGen” 或 “公司”）是一家臨床階段的生物技術公司，專注於創新型自體、異體和CAR-NK自然殺傷（“NK”）自然殺傷（“NK”）細胞療法的開發和商業化。該公司今天宣佈，NKGen Biotech董事長兼首席執行官Paul Y. Song醫學博士將介紹其NK細胞療法的詳細信息神經退行性疾病，審查其帕金森氏病的臨床前數據，並重點介紹該公司最近完成的1期臨床的臨床安全性和有效性數據在將於2024年4月23日至25日在馬薩諸塞州波士頓舉行的第12屆阿爾茨海默氏症和帕金森氏症藥物研發年度峯會上，對自體自然殺傷細胞療法 SNK01 進行了試驗。
| Presentation Details: | |
| Title: | Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01 |
| Conference Track: | Translational -- Harnessing Cell Therapy & Senescence to Reduce Alzheimer's Pathology in Preclinical Research |
| Date and Time: | Thursday, April 25, 2024, 2:00 pm ET |
| 演示詳情： | |
| 標題： | 評估使用自體 SNK01 治療神經變性的過繼細胞免疫療法 |
| 會議軌道： | 轉化——在臨床前研究中利用細胞療法和衰老來減少阿爾茨海默氏症的病理狀況 |
| 日期和時間： | 美國東部時間 2024 年 4 月 25 日星期四下午 2:00 |
Dr. Song's presentation will detail how enhanced natural killer cells can maximize the body's ability to destroy diseased and abnormal cells and provide a review of NK cell therapy as an alternative treatment modality to resolve neurodegeneration by harnessing the body's natural immune system, including a discussion on the scientific rationale behind the use of NK cell therapy for the treatment of Parkinson's disease. Dr. Song will also present clinical safety and efficacy data from the Company's recently completed Phase 1 clinical trial evaluating autologous SNK01 NK cell therapy in patients with Alzheimer's disease (NCT04678453).
宋博士的演講將詳細介紹增強的自然殺傷細胞如何最大限度地發揮人體破壞病變和異常細胞的能力，並回顧NK細胞療法作爲利用人體自然免疫系統解決神經變性的替代治療方式，包括討論使用NK細胞療法治療帕金森氏病背後的科學依據。宋博士還將介紹該公司最近完成的評估阿爾茨海默氏病（NCT04678453）患者自體 SNK01 NK細胞療法的1期臨床試驗的臨床安全性和有效性數據。
A copy of the presentation will be available on the Scientific Publications page of the Company's website at once the presentation has concluded. Previously disclosed Phase 1 data on the positive effects of SNK01 on amyloid, tau and neuroinflammation biomarkers, which may not be included in this conference presentation, can also be found on the Scientific Publications page.
演講結束後，該演示文稿的副本將在公司網站的科學出版物頁面上公佈。先前披露的關於 SNK01 對澱粉樣蛋白、tau 和神經炎症生物標誌物積極作用的第一階段數據，這些數據可能未包含在本次會議演講中，也可以在科學出版物頁面上找到。
譯文內容由第三人軟體翻譯。